Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer.

Abstract

BACKGROUND:

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. No more than 30% of HCC patients receive curative treatment. Factors limiting curative therapy include tumor size and degree of liver impairment.

OBJECTIVE:

To develop a cure for medium (3.1-5.0 cm) and large (>5 cm) tumors in seriously impaired livers.

METHOD:

Combine radiofrequency ablation (RFA) with lyso-thermosensitive liposomal doxorubicin (LTLD).

RESULTS/CONCLUSIONS:

RFA is used safely in patients with medium/large tumors and severe liver impairment; unclear tumor margins limit its curative efficacy. LTLD concentrates in the liver, where the anti-HCC chemotherapeutic, doxorubicin, is released into tumor margins by hyperthermia. RFA/LTLD can treat Child-Pugh class A-B patients with tumors up to 7 cm, a substantial increase in curable patients.

• Authors: Ronnie T P Poon, Nicholas Borys
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 10 Issue 2 Pg. 333-43 (Feb 2009) ISSN: 1744-7666 [Electronic] England
• PMID: 19236203 (Publication Type: Journal Article, Review)

Chemical References

• Antibiotics, Antineoplastic
• Liposomes
• Lysophosphatidylcholines
• Doxorubicin

Topics

• Animals
• Antibiotics, Antineoplastic (administration & dosage, pharmacology, therapeutic use)
• Carcinoma, Hepatocellular (pathology, therapy)
• Catheter Ablation (methods)
• Chemotherapy, Adjuvant
• Clinical Trials as Topic
• Doxorubicin (administration & dosage, pharmacology, therapeutic use)
• Hot Temperature
• Humans
• Hyperthermia, Induced
• Liposomes
• Liver Neoplasms (pathology, therapy)
• Lysophosphatidylcholines
• Randomized Controlled Trials as Topic
• Treatment Outcome